How a Simple Worm May Hold the Key to Stopping Parkinson’s and Alzheimer’s

Scientists have discovered a link between how the body manages copper and neurodegenerative diseases like Parkinson’s and Alzheimer’s. Using a gene called swip-10 in roundworms, their research suggests that restoring copper balance could lead to new treatments for these disorders. Studies on simple organisms often help develop new medical therapies. A famous example is the 2020 Nobel Prize in Chemistry for CRISPR, a gene-editing technology. This discovery, originally based on bacteria research, has led to treatments for various disorders and continues to influence future medical advancements. Recognizing the importance of such research, scientists led by Dr. Randy D. Blakely at Florida Atlantic University have uncovered findings that could eventually help treat human neurodegenerative diseases. Their work began with a tiny roundworm known as Caenorhabditis elegans, a common model in neuroscience because its genes can easily be studied to understand brain function. In their study, published in the Proceedings of the National Academy of Sciences, the team found that the worm gene swip-10 helps control copper levels. Copper, a vital nutrient, is crucial for brain health as it supports energy production and protects cells from damage. A lack of proper copper regulation in brain cells can lead to the death of neurons, which is seen in diseases like Parkinson’s and Alzheimer’s. Further research revealed that mutations in swip-10 cause neurons in the worms to deteriorate early, similar to what happens in Parkinson’s disease. The scientists also found that a related gene in humans, called MBLAC1, is linked to certain forms of Alzheimer’s. Mutations in this gene disrupt copper balance, leading to poor brain and heart health. By supplementing copper in the diet or using a drug that boosts copper levels, the researchers were able to restore cell function and prevent neuron death in the worms. This suggests that regulating copper could be key to treating neurodegenerative diseases. Interestingly, the antibiotic ceftriaxone, which binds to the MBLAC1 protein, has shown promise in protecting brain cells. While ceftriaxone hasn’t been effective in clinical use, the team believes that understanding how copper balance works could help design better drugs in the future. This research was supported by various institutions, including the Florida Department of Health and the National Institutes of Health, and could lead to significant advancements in understanding and treating neurodegenerative diseases by focusing on copper regulation.